top
Please input keywords
Order
*Country
日本
アメリカ
中国
オーストラリア
シンガポール
イギリス
フランス
ドイツ
スイス
イタリア
カナダ
韓国
オランダ
ベルギー
スウェーデン
その他
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-App NL-G-F mice
Strain Name

C57BL/6JNifdc-Apptm1(Abeta*K670N*M671L*G676R*F681Y*R684H*E693G*I716F)Bcgen/Bcgen

Common Name 

B-App NL-G-F mice

Background C57BL/6JNifdc Catalog number

113062

Aliases 

AAA, AD1, PN2, ABPP, APPI, CVAP, ABETA, PN-II, preA4, CTFgamma, alpha-sAPP

NCBI Gene ID

351

Description


  • Amyloid precursor protein (APP) is a 100-140 kDa transmembrane glycoprotein that plays a key role in the pathogenesis of Alzheimer's disease (AD). In the disease state, β-secretase and γ-secretase aberrantly cleave APP, resulting in the release of amyloid β (Aβ) peptides Aβ40 and Aβ42, which are neurotoxic fragments capable of oligomerizing, aggregating, and subsequently forming plaques.
  • Gene editing strategy: The B-App NL-G-F mice carried humanizing Aβ region R684H, F681Y, and G676R mutations, and the KM670/671NL (Swedish) mutation in exon 16 as well as the E693G (Arctic) and I716F (Beyreuther/Iberian) mutations in exon 17 of the mouse App gene. This mice expressed humanized Aβ with three familial AD mutations.
  • mRNA expression analysis: The App mRNA in B-App NL-G-F mice contained a humanized Aβ sequence (G676R*F681Y*R684H), along with Swedish (K670N*M671L), Beyreuther/Iberian (I716F), and Arctic mutations (E693G). These point mutations were confirmed via Sanger Sequencing.
  • Protein expression analysis: The humanized Aβ was only detected in brain of homozygous B-App NL-G-F mice, but not in wild type mice.
  • Immunohistochemistry analysis: The Aβ plaques was exclusively detectable in homozygous B-App NL-G-F mice. Compared to wild-type mice, the number of activated astrocytes and microglia cells in the cortex and hippocampus significantly increases, indicating the presence of inflammation in the brain.
  • Application: This product is used for pharmacodynamics and safety evaluation of Alzheimer's disease (AD).

Targeting strategy

Gene targeting strategy for B-App NL-G-F mice. The B-App NL-G-F mice carried humanizing Aβ region R684H, F681Y, and G676R mutations, and the KM670/671NL (Swedish) mutation in exon 16 as well as the E693G (Arctic) and I716F (Beyreuther/Iberian ) mutations in exon 17 of the mouse App gene. This B-App NL-G-F mice expressed humanized Aβ with three familial AD mutations.

mRNA expression analysis

from clipboard

Species specific analysis of App gene expression in wild-type C57BL/6JNifdc mice and homozygous B-App NL-G-F mice by RT-PCR. Brain RNA were isolated from wild-type C57BL/6J mice (+/+) and homozygous B-App NL-G-F mice (Mut/Mut), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mouse App primers. Mouse App mRNA was detectable in wild-type C57BL/6J and homozygous mice, and point mutations were confirmed via Sanger Sequencing.

Protein expression analysis

from clipboard

Western blot analysis of APP protein expression in homozygous B-App NL-G-F mice. Various tissue lysates were collected from wild-type C57BL/6J mice (+/+) and homozygous B-App NL-G-F mice (Mut/Mut), and then analyzed by western blot with species-specific anti-amyloid precursor antibody (Abcam, ab133588). 50 μg total proteins were loaded for western blotting analysis. Human Abeta sequence was detected in brain of homozygous B-App NL-F mice, but not in wild-type mice.

from clipboard

Western blot analysis of APP protein expression in homozygous B-App NL-G-F mice. Various tissue lysates were collected from wild-type C57BL/6J mice (+/+) and homozygous B-App NL-G-F mice (Mut/Mut), and then analyzed by western blot with species-specific anti-amyloid precursor antibody (Abcam, ab133588). 50 μg total proteins were loaded for western blotting analysis. Human Abeta sequence was detected in brain of homozygous B-App NL-F mice, but not in wild-type mice.

Immunohistochemistry analysis

from clipboard

Histopathological analysis of brain in homozygous B-App NL-G-F mice. Brain was collected from wild-type (WT) mice, homozygous B-App NL-G-F mice and processed into paraffin sections. The Aβ plaque in the cortex and hippocampus of 6-month-old wild-type C57BL/6J mice and homozygous B-App NL-G-F mice was detected by IHC with anti-human β-Amyloid antibody (CST, #8243S). The Aβ plaque was exclusively detectable in homozygous B-App NL-G-F mice, but not in wild-type mice. There is no significant difference in Aβ plaques between female and male mice.

from clipboard

Histopathological analysis of brain in homozygous B-App NL-G-F mice. Brain was collected from wild-type (WT) mice, homozygous B-App NL-G-F mice and processed into paraffin sections. The expression of GFAP in the cortex and hippocampus of 6-month-old C57BL/6J mice and homozygous B-App NL-G-F mice was detected by IHC with anti-GFAP antibody (abcam, ab68428). Compared to wild-type mice, the number of activated astrocytes in the cortex and hippocampus significantly increases, indicating the presence of inflammation in the brain.

from clipboard

Histopathological analysis of brain in homozygous B-App NL-G-F mice. Brain was collected from wild-type (WT) mice, homozygous B-App NL-G-F mice and processed into paraffin sections. The expression of Iba1 in the cortex and hippocampus of 6-month-old C57BL/6J mice and homozygous B-App NL-G-F mice was detected by IHC with anti-Iba1 antibody (abcam, ab178846). Compared to wild-type mice, the number of activated microglias in the cortex and hippocampus significantly increases, indicating the presence of inflammation in the brain.